Telmisartan in Mild to Moderate Hypertensive Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Telmisartan

Criteria

Inclusion Criteria:

• Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex

Exclusion Criteria:

• Suspected or known diagnosis of arterial hypertension with a secondary cause

• Women who were not using an effective method of contraception, or who were pregnant, or breast-feeding

• Systolic blood pressure > 200 mm Hg or diastolic blood pressure > 115 mm Hg

• Laboratory test values two fold above the upper normal limit

• Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR)

• New York Heart Association class III or IV heart failure

• History of stroke in the 6 months prior to entry into the study

• Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels > 140 mg/dL on 3 consecutive assessments

• Patients who were included in another investigational drug study in the past 30 days